BRPI0820343A2 - Anticorpos de antifator b e seus usos - Google Patents

Anticorpos de antifator b e seus usos

Info

Publication number
BRPI0820343A2
BRPI0820343A2 BRPI0820343A BRPI0820343A BRPI0820343A2 BR PI0820343 A2 BRPI0820343 A2 BR PI0820343A2 BR PI0820343 A BRPI0820343 A BR PI0820343A BR PI0820343 A BRPI0820343 A BR PI0820343A BR PI0820343 A2 BRPI0820343 A2 BR PI0820343A2
Authority
BR
Brazil
Prior art keywords
antibodies
factor
antifactor
cnv
amd
Prior art date
Application number
BRPI0820343A
Other languages
English (en)
Portuguese (pt)
Inventor
Deforge Laura
Van Lookeren Campagne Menno
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0820343(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0820343A2 publication Critical patent/BRPI0820343A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0820343A 2007-11-08 2008-11-06 Anticorpos de antifator b e seus usos BRPI0820343A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US264807P 2007-11-08 2007-11-08
PCT/US2008/082621 WO2009061910A1 (en) 2007-11-08 2008-11-06 Anti-factor b antibodies and their uses

Publications (1)

Publication Number Publication Date
BRPI0820343A2 true BRPI0820343A2 (pt) 2017-08-22

Family

ID=40344464

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820343A BRPI0820343A2 (pt) 2007-11-08 2008-11-06 Anticorpos de antifator b e seus usos

Country Status (15)

Country Link
US (4) US8158762B2 (cg-RX-API-DMAC7.html)
EP (1) EP2209807A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011503094A (cg-RX-API-DMAC7.html)
KR (1) KR20100105587A (cg-RX-API-DMAC7.html)
CN (1) CN101918444A (cg-RX-API-DMAC7.html)
AR (1) AR069233A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008323939A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0820343A2 (cg-RX-API-DMAC7.html)
CA (1) CA2704973A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008003313A1 (cg-RX-API-DMAC7.html)
IL (1) IL205577A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010005115A (cg-RX-API-DMAC7.html)
PE (1) PE20091022A1 (cg-RX-API-DMAC7.html)
TW (1) TW200927170A (cg-RX-API-DMAC7.html)
WO (1) WO2009061910A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
TWI407953B (zh) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical 用於調節補體因子ｂ（ｃｆｂ）表現的醫藥組合物
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
CN114890943A (zh) 2013-11-15 2022-08-12 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途
EA201892225A1 (ru) 2016-04-04 2019-09-30 БИОВЕРАТИВ ЮЭсЭй ИНК. АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
AU2021261257A1 (en) 2020-04-20 2022-12-22 Genzyme Corporation Humanized anti-complement factor Bb antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
NZ567483A (en) 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
EP2134173A4 (en) 2007-03-01 2010-11-10 Wellstat Ophthalmics Corp TREATMENT OF DISEASES SIGNED BY IGNITION

Also Published As

Publication number Publication date
US20180037667A1 (en) 2018-02-08
CL2008003313A1 (es) 2010-02-05
JP2011503094A (ja) 2011-01-27
WO2009061910A1 (en) 2009-05-14
PE20091022A1 (es) 2009-07-16
AU2008323939A1 (en) 2009-05-14
TW200927170A (en) 2009-07-01
CA2704973A1 (en) 2009-05-14
US20120230997A1 (en) 2012-09-13
US20090123469A1 (en) 2009-05-14
IL205577A0 (en) 2010-11-30
US20160024224A1 (en) 2016-01-28
US8158762B2 (en) 2012-04-17
EP2209807A1 (en) 2010-07-28
KR20100105587A (ko) 2010-09-29
CN101918444A (zh) 2010-12-15
MX2010005115A (es) 2010-05-27
AR069233A1 (es) 2010-01-06

Similar Documents

Publication Publication Date Title
CY1116062T1 (el) Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα
BRPI0820343A2 (pt) Anticorpos de antifator b e seus usos
MX2021011394A (es) Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico.
WO2012100142A3 (en) Treatments for retinal disorders
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
MX347391B (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de degeneración macular relacionada con la edad (amd).
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
NI201900085A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
ECSP12011692A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
HK1231367A1 (zh) 抗体药物偶联物、试剂和制备方法及其治疗用途
MY171920A (en) Prevention and treatment of ocular conditions
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
WO2009097468A3 (en) Drug delivery devices, kits and methods therefor
BR112014008759A2 (pt) tratamento de doença ocular
WO2007133800A3 (en) Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
NI201300070A (es) Ureas asimétricas y usos médicos de las mismas
EA201100462A1 (ru) Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств
CR20110294A (es) Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
BR112017021083A2 (pt) piridopirimidinonas e seu uso como moduladores do receptor de nmda
MY184647A (en) Arylated camphenes, processes for their preparation and uses thereof
CY1122496T1 (el) Παραγωγα αιμινης με αντιβακτηριακη και αντιιικη δραστικοτητα
CR20110289A (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
BR112017007095A2 (pt) conjugados e derivados de prostaglandina para tratamento de glaucoma e hipertensão ocular

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.